Biotech | March 16, 2022
Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
Tapestri Platform powers Nature Cardiovascular Research publication that identifies two somatic mutations associated with sporadic brain blood vessel disorder
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
Most recently, Rollins was the Chief Information Officer at UnitedHealthcare
First and only once-weekly patch for convenient, well-tolerated delivery of most used drug for the treatment of Alzheimer's-related dementia
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
The money will be donated to the United Nations Children’s Fund (UNICEF)
Subscribe To Our Newsletter & Stay Updated
